Occam Places Steve Colletti as CSO of Korro Bio
Korro Bio is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and common diseases. The company has raised over $200M across two rounds of financing. Top-tier investors include Atlas, Qiming, Fidelity, Point72, NEA, Eventide, Cormorant Asset Management, and Citadel.
In Colletti, Korro captures an RNA domain expert and a broadly gauged scientific leader who speaks the languages of both chemistry and biology, a bifocal perspective that he has leveraged to great effect across discovery and translation through early clinical development. After a highly successful R&D career at Merck, Colletti effectively transitioned to Biotech with Lodo which was subsequently acquired by Zymergen.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.